RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE

Special systems were developed for response assessment of immunooncology drugs. The role and benefits of particular system in assessing the efficacy of different immunotherapy methods are not clear yet. The objective of this study is to compare the responses on ipilimab (IPI) or dendritic cell vacci...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: A. V. Novik, E. V. Yaremenko, E. M. Anokhina, T. L. Nehaeva, A. I. Semenova, D. Kh. Latipova, S. A. Protsenko, I. A. Baldueva
Formaat: Artigo
Taal:Russo
Gepubliceerd in: Tomsk National Research Medical Center of the Russian Academy of Sciences 2019-09-01
Reeks:Sibirskij Onkologičeskij Žurnal
Onderwerpen:
melanoma
ipilimumab
dendritic cell vaccines
recist 1.1
irrc
response assessment
immunotherapy
Online toegang:https://www.siboncoj.ru/jour/article/view/1136
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items